Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Jun / Hitting the Bullseye
Discovery & Development Drug Delivery

Hitting the Bullseye

Exosomes help deliver drug into the heart of the tumor

By Stephanie Vine 06/02/2015 1 min read

Share

One of the hurdles for anticancer treaments is the poor tumor penetration of therapeutic agents. Most existing drug delivery systems only transport drugs to tumor cells close to blood vessels but Ji-Ho Park and his team at the Korea Advanced Institute of Science and Technology believe that therapies could be delivered more uniformly by using exosomes. Exosomes can travel between cells and can therefore deliver the compound to the inner cells of the tumor.

“In solid tumors, high interstitial fluid pressure and a dysfunctional lymphatic system impede the delivery of therapeutic molecules into the deep parenchyma at the center of the tumor. Nanoparticle formulations, such as the clinically approved PEGylated liposomal doxorubicin (Doxil) and albumin-bound paclitaxel (Abraxane), can alter the pharmacokinetics of drugs and enhance the permeability of tumor vessels. However, many of the therapeutic compounds delivered systemically through currently available nanocarriers remain predominantly in the perivascular region around the edge of the tumor, which reduces the overall therapeutic effect,” says Park. Park and his colleagues packaged a light-sensitive anticancer drug into exosomes using liposome-based cell engineering, with promising results. “We found that exosomes play a key role in intercellular migration of exogenous hydrophobic compounds through multiple cell layers,” he says. “Using such exosome-mediated cargo delivery, we demonstrated that hydrophobic photosensitizers delivered to the plasma membrane of the outermost cell layer spread throughout the entire spheroid over a 48 hour period via intercellular migration of exosomes, resulting in significant therapeutic effects under irradiation.” Park adds, “We have received a lot of interest in the work. Many pharmaceutical companies and other people in the industry have asked us to utilize this tumor-penetrating delivery system for improving therapeutic efficacy and reducing systemic toxicity of many therapeutic compounds that failed when administered by themselves.” The team believe that their work has applications in a variety of diseases, to deliver chemotherapeutics across challenging tissue barriers.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. J. Lee et al., “Liposome-Based Engineering of Cells To Package Hydrophobic Compounds in Membrane Vesicles for Tumor Penetration,” Nano Letters (2015), DOI: 10.1021/nl5047494.

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

Managing Change in Devices for Patients
Drug Delivery
Managing Change in Devices for Patients

June 21, 2024

4 min read

We need to step away from assumptions on device interchangeability and find out what patients really want

Dosing to Circadian Rhythm
Drug Delivery
Dosing to Circadian Rhythm

December 1, 2014

0 min read

Could medicines be made more effective with better timing?

Connecting the Dots in Drug Delivery
Drug Delivery
Connecting the Dots in Drug Delivery

December 1, 2014

0 min read

The days of “low-hanging fruit” in drug discovery are a thing of the past...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.